Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2015-04-06
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies auranofin in treating patients with epithelial ovarian,
primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin,
may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube
cancer.